Who
Henry Brem
Director
Company insider
Files Form 4 as: Director, Galectin Therapeutics; Director, Alseres Pharmaceuticals Inc /de.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 5 Feb 2007
- Last trade
- 12 Mar 2026
- Last filed
- 17 Mar 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Mar 2026filed 17 Mar 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 12 Mar 2026filed 17 Mar 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 14 Jan 2009filed 16 Jan 2009 | Alseres Pharmaceuticals Inc /deoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 6 Dec 2007filed 7 Dec 2007 | Alseres Pharmaceuticals Inc /deoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Mar 2007filed 20 Mar 2007 | Boston Life Sciences Inc /deoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Feb 2007filed 7 Feb 2007 | Boston Life Sciences Inc /deoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.